NCT06081777View on ClinicalTrials.gov

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

RecruitingOBSERVATIONAL

Enrollment

65

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions

NSCLC

Trial Locations (1)

100142

RECRUITING

Yuyan Wang, Beijing

All Listed Sponsors

collaborator

Geneplus-Beijing Co. Ltd.

INDUSTRY

lead

Peking University Cancer Hospital & Institute

OTHER